Turn Therapeutics Announces Vaccine Breakthrough: Validates 100% VSV Recovery from Petrolatum Carrier at 24 and 72 Hours
Turn Therapeutics, a clinical-stage pharmaceutical and medical device company, announced today that it has achieved a critical milestone in its effort to reduce dependency on cold-storage for vaccines.
Turn Therapeutics Launches Final Crowdfund Round Ahead of Eczema Trial Enrollment, Engages Clear Street to Explore Public Markets
Turn Therapeutics, a clinical-stage biotechnology company pioneering next-generation topical therapies, today announced the launch of its final crowdfund investment round in tandem with the upcoming initiation of a controlled clinical trial evaluating its flagship, non-steroidal topical platform in patients with moderate to severe eczema.
Turn Therapeutics Achieves 24-Hour Stability for Live Vaccine in Intranasal Oil Suspension at Room Temperature, Marking Major Milestone Toward Improving Vaccine Access
Turn Therapeutics has successfully maintained a live vaccine's viability for 24 hours at room temperature using its oil suspension technology. This breakthrough -- which entailed stabilizing a well-recognized vaccine vector in a viscous oil delivery system -- is a step toward making it easier to store, transport, and administer vaccines globally, especially in regions with limited infrastructure for refrigerated and deep-freeze vaccine storage.
Turn Therapeutics Secures $75 Million Investment Commitment Tied to Public Listing
Turn Therapeutics, an innovator in advanced wound and dermatology solutions, is pleased to announce a significant investment commitment from GEM Global Yield LLC SCS ("GEM"), a $3.4 billion private equity and alternative investment group.
Turn Therapeutics Atopic Dermatitis Candidate Reduces Disease Severity by 57% In-Vivo
In a widely cited in-vivo model of atopic dermatitis, Turn Therapeutics' atopic dermatitis candidate showed a dramatic reduction in disease severity versus placebo.
Turn Therapeutics invites public investment for expansion of flagship wound formula into eczema, toenail fungus
Turn Therapeutics, an innovative biotech company, launched its first public investment campaign today to fund clinical trials of its Food and Drug Administration-cleared antimicrobial ointment for two potential new drug indications: moderate to severe eczema and onychomycosis, or toenail fungus.
Turn Therapeutics Announces Human Trial Data for COVID-19 Early Intervention Candidate
Turn Therapeutics, a biotechnology company specializing in advanced wound care and infection control, today announced the results of its Phase 2B, placebo controlled trial of Hexagen Antimicrobial Ointment in treating mild to moderate infected COVID-19 patients. This double-blinded study enrolled 80 people across three sites in Panama to evaluate safety and efficacy of Hexagen Antimicrobial as an early intervention against COVID-19. Specifically, the study investigated intranasal use of FDA-cleared Hexagen immediately post-positive PCR test as a means to reduce disease duration, as well as the safety of consistent intranasal use of Hexagen over 5 and 10 days. Efficacy results have confirmed in-vitro virucidal data, while safety results have confirmed in-vivo biocompatibility data for use on mucous membranes.
